- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
CDKN2A Antibody Mouse Monoclonal / p16INK4a [clone rCDKN2A/7659] (V5276)
Email: info@nsjbio.com
| Catalog No | Formulation | Size | Price (USD) | ||
|---|---|---|---|---|---|
|
V5276-100UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide | 100 ug | 559 | |
|
|
V5276-20UG | 0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide | 20 ug | 259 | |
|
|
V5276SAF-100UG | 1 mg/ml in 1X PBS; BSA free, sodium azide free | 100 ug | 559 |
|
| Availability | 1-3 business days |
| Species Reactivity | Human |
| Format | Purified |
| Host | Mouse |
| Clonality | Recombinant Mouse Monoclonal |
| Isotype | Mouse IgG1, kappa |
| Clone Name | rCDKN2A/7659 |
| Purity | Protein A/G affinity |
| UniProt | P42771 |
| Localization | Nucleus, Cytoplasm |
| Applications | Immunohistochemistry (FFPE) : 1-2ug/ml for 30 min at RT |
| Limitations | This CDKN2A antibody is available for research use only. |
|
Review this product on BioCompare and get a $20 Amazon gift card
|
Related Products
|
CDKN2A antibody recognizes Cyclin-dependent kinase inhibitor 2A, the tumor suppressor protein widely known as p16INK4a, encoded by the CDKN2A gene on chromosome 9p21.3. CDKN2A Antibody Mouse Monoclonal is developed to detect this key regulator of cell cycle progression in research applications involving normal and neoplastic tissues. The p16INK4a protein localizes predominantly to the nucleus, with additional cytoplasmic distribution, where it binds CDK4 and CDK6 to inhibit phosphorylation of the retinoblastoma protein and block the transition from G1 to S phase.
p16INK4a antibody, also referred to as CDKN2A antibody and INK4a antibody in the literature, targets a central component of the RB pathway. The CDKN2A locus encodes multiple distinct tumor suppressor proteins through alternative reading frames, including p14ARF, but p16INK4a specifically inhibits cyclin D-CDK4 and cyclin D-CDK6 complexes. Loss of CDKN2A function through deletion, mutation, or promoter methylation is one of the most frequent molecular events in melanoma, pancreatic carcinoma, glioma, bladder carcinoma, and other malignancies.
In normal tissues, p16INK4a expression is typically low in proliferating cells but increases during cellular senescence or in response to oncogenic stress. Marked overexpression is commonly observed in high-risk human papillomavirus-associated lesions, including cervical intraepithelial neoplasia and carcinoma, where viral inactivation of RB results in compensatory upregulation of p16INK4a. As a result, CDKN2A antibody is widely used in studies investigating viral oncogenesis, cell cycle dysregulation, and tumor suppressor pathway alterations.
Structurally, p16INK4a contains ankyrin repeat domains that mediate its interaction with CDK4 and CDK6. By maintaining RB in a hypophosphorylated state, p16INK4a enforces cell cycle arrest and prevents inappropriate S phase entry. Disruption of this regulatory pathway contributes directly to uncontrolled cellular proliferation and tumor development.
The mouse monoclonal clone rCDKN2A/7659 provides specific detection of p16INK4a in formalin-fixed tissues and cell-based systems. Visualization of nuclear and cytoplasmic staining patterns supports evaluation of CDKN2A expression status and investigation of RB pathway integrity in research applications from NSJ Bioreagents.
Optimal dilution of the CDKN2A antibody mouse monoclonal should be determined by the researcher.
Purified recombinant prokaryotic full-length human protein was used as the immunogen for the CDKN2A antibody mouse monoclonal.
Aliquot the CDKN2A antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.
Powered by Bioz
